On July 1, JP Morgan’s Cory Kasimov reiterated his hold rating on Amgen after the Federal Circuit affirmed the validity of two patents covering autoimmune treatment Enbrel.“In spite of potential multiple expansion, we need more visibility on clinical data from each program (and how ‘510 and TSLP stack up to competition) in order to get more constructive on Amgen’s overall top-line outlook” Kasimov concludes.